Add this topic to your myFT Digest for news straight to your inbox
Chief must maintain the momentum if he is to leave the drugmaker on a high
Presidential race is one of several factors stirring inflation concerns, Andrew Witty says
New generation of products helps offset drugs facing inexorable rise of generic competition
Two years after sale of oncology arm UK pharma group is again training its sights on the ‘big C’
Proposals will allow manufacturers to produce low-cost generic drugs without risk of legal challenge
When it comes to playing follow the leader mining group has the better strategy than pharma company
Lower dollar and higher commodity prices lift mining stocks, while banks and pharma fall
As group starts formal search for successor, four areas will determine how his tenure will be judged
Andrew Witty is unlucky, and soon to be out of work
News of chief’s departure set to intensify speculation about break-up of pharma group
UK drugmaker has consulted large shareholders on replacing chief executive
Chief executive could be in store for bad news at yearly check-up
If the pharma group can maintain momentum, it will be easier to fend off calls for a break-up
Target of £6bn annual sales from new products to be achieved by 2018 — 2 years earlier than forecast
Warning comes as Lord Rose launches campaign focusing on economic risks of leaving EU
More than 80 companies unite at Davos with call for new economic models for antibiotics
Analysts warn that Mylan submission will weigh on UK drugmaker in ‘key recovery year’
2016 will be critical for UK pharma groups’ divergent strategies
Witty aims to show turnround plan is on track with strong growth in new drugs
It looked to be the growth engine for Big Pharma, but bribery and a flawed system have dashed hopes
International Edition